SCHEMBL6441834

SCHEMBL6441834

COc1cc2c(cc1OC)[C@@H]1CCCC[C@@H]1N=C2c1ccno1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 11/20 0.36
PDE4A P27815 8/20 0.35
PDE4B Q07343 7/20 0.35
PDE4C Q08493 6/20 0.35
MEN1 O00255 1/20 0.33
CHRM1 P11229 1/20 0.33
KMT2A Q03164 1/20 0.33
PDE3A Q14432 1/20 0.33
TNKS O95271 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
NPC1 O15118 3/20 0.31
RAB9A P51151 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441844 1.00 PDE4D (0.36) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL6441838 1.00 PDE4D (0.36) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL6441615 0.82 ALDH1A1 (0.39) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL6441610 0.82 ALDH1A1 (0.39) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL6441614 0.82 ALDH1A1 (0.39) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL6442562 0.79 LMNA (0.39) CHRM1KMT2ARAB9AKDM4EALDH1A1
SCHEMBL6442559 0.79 LMNA (0.39) CHRM1KMT2ARAB9AKDM4EALDH1A1
SCHEMBL6442566 0.79 LMNA (0.39) CHRM1KMT2ARAB9AKDM4EALDH1A1
SCHEMBL2264080 0.78 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL6445516 0.78 FGFR1 (0.42) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP claimed
US-6884802-B2 6-heteroarylphenanthridines ALTANA PHARMA AG (DE) 2005-04-26 US disclosed
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP disclosed
US-20040038979-A1 Treating airway disorders such as asthma. ALTANA PHARMA AG (DE) 2004-02-26 US disclosed
EP-1303506-A1 6-HETEROARYLPHENANTHRIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-04-23 EP disclosed
WO-2002006270-A1 NOVEL 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038979-A1 Treating airway disorders such as asthma. PTGER4, PDE4B, PDE4A PDE4D 20/4885PDE4A 3/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.